Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Study: Success Stories in Biotech Consultancy Services by EvoLV

Jan 26, 2026

Introduction to EvoLV's Biotech Consultancy

The biotech industry is a rapidly evolving field, and navigating its complexities requires expertise and strategic insight. EvoLV has emerged as a leader in biotech consultancy, offering tailored solutions to help companies overcome challenges and achieve their goals. This case study explores some of the success stories from EvoLV's consultancy services, demonstrating their impact on client growth and innovation.

biotech consultancy

Enhancing Research and Development

One of EvoLV's key areas of focus is enhancing research and development (R&D) for biotech firms. By leveraging their extensive knowledge and industry connections, EvoLV helps companies streamline their R&D processes. This involves identifying potential bottlenecks, suggesting innovative technologies, and fostering collaborations that drive progress.

For instance, a mid-sized biotech company struggling with delayed product development timelines sought EvoLV's expertise. Through strategic guidance, EvoLV helped them reduce their R&D cycle time by 30%, enabling faster market entry and improved competitive positioning.

Regulatory Compliance and Strategy

Regulatory compliance is a critical aspect of the biotech industry. EvoLV assists clients in navigating complex regulatory landscapes, ensuring that their products meet all necessary standards. Their consultants provide insights into the latest regulatory changes and how they impact product approval processes.

regulatory compliance

In one case, EvoLV supported a startup in obtaining FDA approval for a novel therapeutic. By developing a comprehensive regulatory strategy, EvoLV enabled the client to achieve compliance efficiently, saving valuable resources and time.

Market Entry and Expansion

Successfully entering new markets or expanding existing ones can be daunting. EvoLV offers strategic market insights and entry strategies, helping clients identify opportunities and build effective market penetration plans. Their expertise in market analysis and competitive positioning is invaluable for companies looking to grow.

A notable success story involved a biotech firm aiming to enter the European market. EvoLV's consultants provided a detailed market assessment and devised a successful entry strategy, resulting in a significant increase in market share within the first year.

market entry strategy

Building Strategic Partnerships

Partnerships play a crucial role in the biotech sector, offering opportunities for resource sharing, innovation, and growth. EvoLV facilitates the development of strategic alliances, connecting clients with potential partners that complement their strengths and objectives.

Through EvoLV's network, a client was able to form a partnership with a leading pharmaceutical company. This collaboration not only enhanced their product development capabilities but also accelerated their time to market, showcasing the power of strategic partnerships.

Conclusion

EvoLV's biotech consultancy services have proven to be instrumental in driving success for many biotech companies. By focusing on R&D enhancement, regulatory compliance, market strategies, and partnerships, EvoLV helps clients navigate industry challenges and achieve their objectives. These success stories underscore the value of expert consultancy in the dynamic biotech landscape.

business success